Abstract:Objective:To explore the feassibility to edit human p53 and PTEN,two tumor suppressor genes,by CRISPR-Cas9 technology and to evaluate the editing efficiency in vitro,and to provide the experimental study tools for transforming primary healthy cells into malignant tumor cells and establishment of humanized mouse models with human oncogenesis in vivo.Methods:The single-guide RNA(sgRNA)sequences were designed to target the common exon regions of p53 and PTEN mRNA isoforms based on software analysis,that could predict their gene editing efficiency.The sgRNAs with high scores were selected and cloned into Cas9-P2A-GFP plasmid to construct sgRNA-Cas9-P2A-GFP vector that co-expressed sgRNA,Cas9 and GFP.The 293T cells in logarithmic growth phase were transfected with the sgRNA-Cas9-P2A-GFP vector(experimental group)or PBS(control group)by Lipofectamine 2000.After two-week expansion,the GFP-positive 293T cells were purified by flow cytometric sorter,whose genomic DNA was extracted for further analysis.The DNA fragments containing the sgRNA targeting site were amplified from the extracted genomic DNA by PCR and purified by gel extraction.Then they were linked into the pEASY-Blunt Zero cloning vector and transformed into competent E.coli cells.The single colonies formed by pEASY-Blunt Zero vector transformed cells were used to extract the plasmid for DNA sequencing.And the sequencing results of control group and experimental group were compared to judge the gene editing efficiency.Results:Over 82% of the sgRNA-Cas9-P2A-GFP transfected cells were found to express GFP gene after flow sorting in experimental group,which was significantly higher than that of the pre-sorted cells(P<0.05).Genomic DNA was extracted from the sorted cells after expansion and used as PCR template.The length of the amplified fragments containing the p53 mutation site was 612 bp,while the lengths of the amplified fragments containing the PTEN-1/PTEN-2 mutation site were 667 and 947 bp.The results of sequencing showed that the efficiency of editing induced by p53-1,p53-2 and PTEN-2 sgRNA were 54.5%,45.5% and 33.3%,respectively. Conclusion:The sgRNAs p53-1,p53-2 and PTEN-2 designed for p53 and PTEN can successfully guide Cas9-mediated site-specific genome editing with high efficiency at the genome level.

Synthesis of RNA-based Gene Regulatory Devices for Redirecting Cellular Signaling Events Mediated by P53

Polymeric Nanostructure Compiled with Multifunctional Components to Exert Tumor-Targeted Delivery of Antiangiogenic Gene for Tumor Growth Suppression

An engineered DNA aptamer-based PROTAC for precise therapy of p53-R175H hotspot mutant-driven cancer

Cell‐Specific Control of Mammalian Gene Expression Using DNA Repair Inducible Ribozyme Switches

Precise tumor immune rewiring via synthetic CRISPRa circuits gated by concurrent gain/loss of transcription factors

CRISPR-based molecule-regulatory expression platform for specific immunotherapy of cancer

A revolutionary tool: CRISPR technology plays an important role in construction of intelligentized gene circuits

Programmable Synthetic Protein Circuits for the Identification and Suppression of Hepatocellular Carcinoma

Small-Molecule Modulators Of P53 Family Signaling And Antitumor Effects In P53-Deficient Human Colon Tumor Xenografts

Synthetic mRNA nanoparticle-mediated restoration of p53 tumor suppressor sensitizes p53 -deficient cancers to mTOR inhibition.

High-resolution and programmable RNA-IN and RNA-OUT genetic circuit in living mammalian cells

Advancements in p53-Based Anti-Tumor Gene Therapy Research

An Efficient Light-Inducible P53 Expression System for Inhibiting Proliferation of Bladder Cancer Cell.

Activating p53 with a Mutant-Specific Small Molecule

[Targeted Down-Regulation of P53 Gene Expression by Individual Antisense RNA in Vitro].

A Dual-Targeting Drug Co-Delivery System for Tumor Chemo- and Gene Combined Therapy.

Tumor-targeted p53-gene therapy enhances the efficacy of conventional chemo/radiotherapy

Tumor targeted genome editing mediated by a multi-functional gene vector for regulating cell behaviors.

Decreased DNA Damage and Improved P53 Specificity of RITA Analogs

An Inducible CRISPR-dCas9-Based Transcriptional Repression System for Cancer Therapy

Screening and efficiency verification of CRISPR-Cas9 single-guide RNA against human tumor suppressor gene p53 and PTEN